In silico evaluation of promising drugs and natural compounds as HTLV-1 reverse transcriptase inhibitors
In Silico Research in Biomedicine · 2026-11 · 100727
DOI: 10.1016/j.insi.2026.100727 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Silico Research in Biomedicine, 2026-11. Verfasst von Milena Cristina Martins da Silva und 10 weiteren Autor:innen. Die Arbeit nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
HTLV-1 is a retrovirus associated with diseases such as ATLL and HAM/TSP. The lack of specific antiviral therapies highlights the need to identify new compounds capable of inhibiting key HTLV-1 targets, such as reverse transcriptase (RT)—an essential enzyme for viral replication, particularly during the early and acute phases of infection. This study aimed to identify and prioritize structurally stable binding candidates targeting the HTLV-1 RT using computational drug design strategies. To this end, a three-dimensional structure of HTLV-1 RT was constructed via homology modeling and validated through structural analyses. A virtual screening approach was employed, combining compounds from the Drugs-lib library on the MTiOpenScreen server with those identified through a literature review. The most promising molecules were subjected to redocking, molecular dynamics, and pharmacokinetic (ADME) and toxicological predictions. The HTLV-1 RT protein model exhibited satisfactory structural quality, with 93.5% of residues located in favorable regions of the Ramachandran plot. Among the compounds evaluated, zidovudine 3P displayed the lowest binding free energy and was used as a pharmacological control. When considering molecular affinity, dynamic stability, pharmacokinetic properties, and toxicological profiles collectively, ivermectin demonstrated the best overall performance. Cortisuzol and michelamine also showed promising results, whereas TG100801 exhibited good structural stability but had pharmacokinetic and toxicological limitations. Oleanolic acid performed the poorest as a potential TR inhibitor. Thus, the in silico approach identified ivermectin, cortisuzol, and michelamine as the most promising theoretical candidates for future experimental validation, reinforcing the study's potential for the discovery of new drugs against HTLV-1.
Zitieren
APA
Silva, M. C. M. D., Xavier, G. A., Dias, A. D. L., Furtado, J. W. D. R., Nascimento, L. M., Pereira, R. S. B., Gemaque, H. E. D. S., Filho, E. G. D. S., Araujo, A. C. A., Siqueira, A. S., & Sousa, M. S. D. (2026). In silico evaluation of promising drugs and natural compounds as HTLV-1 reverse transcriptase inhibitors. In Silico Research in Biomedicine, 100727. https://doi.org/10.1016/j.insi.2026.100727
Vancouver
Silva MCMD, Xavier GA, Dias ADL, Furtado JWDR, Nascimento LM, Pereira RSB, et al. In silico evaluation of promising drugs and natural compounds as HTLV-1 reverse transcriptase inhibitors. In Silico Research in Biomedicine. 2026:100727. doi:10.1016/j.insi.2026.100727
BibTeX
@article{Silva2026,
author = {Silva, Milena Cristina Martins da and Xavier, Gabriel Albuquerque and Dias, Anderson de Lima and Furtado, Jhone Willian da Rocha and Nascimento, Luciana Monteiro and Pereira, Renan Stefferson Barradas and Gemaque, Henrique Eron da Silva and Filho, Ednilson Gregorio da Silva and Araujo, Antonia Cherlly Aparecida and Siqueira, Andrei Santos and Sousa, Maísa Silva de},
title = {In silico evaluation of promising drugs and natural compounds as HTLV-1 reverse transcriptase inhibitors},
journal = {In Silico Research in Biomedicine},
year = {2026},
pages = {100727},
doi = {10.1016/j.insi.2026.100727}
}
EUVIMED